Lonza Gro - LZAGY STOCK NEWS

Boehringer Ingelheim has licensed Synaffix's ADC technology to expand its oncology portfolio. The partnership aims to develop advanced antibody-drug conjugates (ADCs) for cancer treatment, combining antibodies' targeting ability with potent cancer-killing drugs for precise delivery to cancer cells.

The agreement involves Synaffix providing access to its proprietary ADC technologies for multiple targets, with the first target already nominated. The deal includes an upfront payment and potential milestone payments up to $1.3 billion, plus royalties on net sales of resulting products.

Synaffix's technology utilizes enzymatic modification of native glycan anchor points on antibodies, enabling the development of enhanced ADCs or bispecifics. This collaboration will allow Boehringer's subsidiary, NBE Therapeutics, to address novel tumor targets and develop first-in-class cancer treatments for high unmet medical needs in oncology.

Synaffix and Elevation Oncology have entered into a licensing agreement for ADC (antibody-drug conjugate) technology development. The deal grants Elevation Oncology access to Synaffix's clinical-stage ADC platform, including GlycoConnect®, HydraSpace®, and toxSYN® technologies, to develop a novel HER3 ADC candidate named EO-1022.

Under the agreement terms, Synaffix could receive up to $368 million in upfront and milestone payments, plus tiered royalties on net sales. Synaffix will manufacture technology components while Elevation Oncology handles research, development, manufacturing, and commercialization of the ADC. The partnership aims to develop treatments for patients with HER3-expressing solid tumors.

Elevation Oncology (ELEV) has nominated EO-1022 as its HER3 ADC development candidate for treating HER3-expressing solid tumors. EO-1022 combines seribantumab, an anti-HER3 monoclonal antibody, with an MMAE payload using Synaffix's technology platform. The company has secured a global license agreement with Synaffix for their GlycoConnect®, HydraSpace®, and SYNstatin E™ technologies.

HER3 is expressed in various cancers including breast cancer, EGFR-mutant non-small cell lung cancer, and pancreatic cancer. The company plans to present preclinical data in 1H 2025 and file an IND application in 2026. Seribantumab has already demonstrated a well-tolerated safety profile in over 900 patients across multiple studies.

Lonza's Synaffix has licensed its ADC technology to BigHat Biosciences following successful preclinical studies. The collaboration combines BigHat's AI/ML-powered antibody design platform, Milliner™, with Synaffix's GlycoConnect™, HydraSpace® and toxSYN® ADC technologies to develop next-generation ADCs. Through Lonza's acquisition of Synaffix, BigHat gains access to Lonza's comprehensive DNA-to-IND ADC development and manufacturing services. The partnership aims to advance BigHat's next-gen ADC program, which is currently at IND-enabling stage and set to become BigHat's first clinical stage program.

NeuroSense Therapeutics (Nasdaq: NRSN) provides a business update for Q1 2024, highlighting key collaborations and positive results from the PARADIGM Study in ALS and Alzheimer's disease. The company is focused on advancing its treatments for neurodegenerative diseases, with plans for further research and clinical trials in the coming months.

HaemaLogiX and Lonza have entered a collaboration to manufacture KappaMab, a monoclonal antibody targeting multiple myeloma, at Lonza's new facility in Guangzhou, China. The agreement will leverage Lonza's regulatory expertise and manufacturing capabilities to support clinical trials for KappaMab. The drug has demonstrated a favorable safety profile in previous trials and has shown improved response rates when combined with lenalidomide. The first clinical batch is expected to be ready by Q4 2022, with trials scheduled to begin shortly thereafter.